Imovax

BIOLOGICAL2 trials

Sponsors

Synermore Biologics Co., Ltd., Washington University School of Medicine

Conditions

Healthy ParticipantsHuman Rabies

Early Phase 1

Washington University WU 409: Immune Responses to Rabies Vaccine.

CompletedNCT07399951

Washington University School of MedicineHealthy Participants

Start: 2023-07-18End: 2025-10-01Updated: 2026-02-10

Phase 1

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines

CompletedNCT02956746

Synermore Biologics Co., Ltd.Human Rabies

Start: 2016-08-31End: 2018-01-31Updated: 2019-02-27

Related Papers

Rabies virus neutralizing activity, pharmacokinetics, and safety of the monoclonal antibody mixture SYN023 in combination with rabies vaccination: Results of a phase 2, randomized, blinded, controlled trial.

2021-09-0316 citations